Regeneron Pharmaceuticals (REGN) Convertible Debt (2011 - 2015)

Regeneron Pharmaceuticals' Convertible Debt history runs 5 years deep, the most recent figure standing at $30.7 million for Q3 2015.

• On a quarterly basis, Convertible Debt fell 89.33% year-over-year to $30.7 million in Q3 2015; TTM through Sep 2015 was $30.7 million, a 89.33% decrease from a year earlier, with the FY2014 full-year figure at $146.8 million, down 54.18% from the prior year.
• Convertible Debt advanced to $30.7 million in Q3 2015 per REGN's latest filing, from $30.4 million in the prior quarter.
• Across five years, Convertible Debt topped out at $326.7 million in Q1 2014 and bottomed at $30.4 million in Q2 2015.
• The 5-year median for Convertible Debt is $286.7 million (2012), against an average of $245.1 million.
• Across the five-year window, Convertible Debt climbed 8.07% in 2014 and sank 89.33% in 2015, its largest moves.
• Year by year, Convertible Debt stood at $275.0 million in 2011, then advanced by 7.82% to $296.5 million in 2012, then rose by 8.03% to $320.3 million in 2013, then slumped by 54.18% to $146.8 million in 2014, then plunged by 79.07% to $30.7 million in 2015.
• Per Business Quant, the three latest REGN Convertible Debt figures stand at $30.7 million (Q3 2015), $30.4 million (Q2 2015), and $144.1 million (Q1 2015).